203 related articles for article (PubMed ID: 15921309)
21. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
22. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O
Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834
[TBL] [Abstract][Full Text] [Related]
23. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
24. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
[TBL] [Abstract][Full Text] [Related]
25. Imatinib: a targeted clinical drug development.
Capdeville R; Silberman S
Semin Hematol; 2003 Apr; 40(2 Suppl 2):15-20. PubMed ID: 12783370
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
Scheinfeld N
J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
[TBL] [Abstract][Full Text] [Related]
27. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
Nardi V; Raz T; Cao X; Wu CJ; Stone RM; Cortes J; Deininger MW; Church G; Zhu J; Daley GQ
Oncogene; 2008 Jan; 27(6):775-82. PubMed ID: 17684485
[TBL] [Abstract][Full Text] [Related]
28. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
Breccia M; Alimena G
Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Druker BJ
Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
[No Abstract] [Full Text] [Related]
30. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
31. Imatinib mesylate for the treatment of chronic myeloid leukemia.
Soverini S; Martinelli G; Iacobucci I; Baccarani M
Expert Rev Anticancer Ther; 2008 Jun; 8(6):853-64. PubMed ID: 18533795
[TBL] [Abstract][Full Text] [Related]
32. Resistance to imatinib mesylate in chronic myeloid leukaemia.
Melo JV; Chuah C
Cancer Lett; 2007 May; 249(2):121-32. PubMed ID: 16949736
[TBL] [Abstract][Full Text] [Related]
33. The biology of chronic myelogenous leukemia: implications for imatinib therapy.
Alvarez RH; Kantarjian H; Cortes JE
Semin Hematol; 2007 Jan; 44(1 Suppl 1):S4-14. PubMed ID: 17292736
[TBL] [Abstract][Full Text] [Related]
34. Flying under the radar: the new wave of BCR-ABL inhibitors.
Quintás-Cardama A; Kantarjian H; Cortes J
Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
[TBL] [Abstract][Full Text] [Related]
35. Current and emerging treatment options in chronic myeloid leukemia.
Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
[TBL] [Abstract][Full Text] [Related]
36. Imatinib. Novartis.
Radford IR
Curr Opin Investig Drugs; 2002 Mar; 3(3):492-9. PubMed ID: 12054102
[TBL] [Abstract][Full Text] [Related]
37. [Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].
Guilhot F
Bull Cancer; 2001 Jul; 88(7):659-60. PubMed ID: 11495817
[No Abstract] [Full Text] [Related]
38. SRCircumventing imatinib resistance.
Deininger MW; Druker BJ
Cancer Cell; 2004 Aug; 6(2):108-10. PubMed ID: 15324693
[TBL] [Abstract][Full Text] [Related]
39. Imatinib and regression of type 2 diabetes.
Veneri D; Franchini M; Bonora E
N Engl J Med; 2005 Mar; 352(10):1049-50. PubMed ID: 15758023
[No Abstract] [Full Text] [Related]
40. [Chronic myeloid leukemia].
Udvardy M
Orv Hetil; 2005 Feb; 146(6):243-7. PubMed ID: 15779811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
